Skip to main content
TipRanks
Go Ultimate75% OFF

Alphatec Holdings (ATEC) AI Stock Analysis

966 Followers
ATEC

Alphatec Holdings

(NASDAQ:ATEC)

Select Model
Rating:49Neutral
Price Target:$8.00â–²(15.27% Upside)
Action:reiterated
Date:10/31/26

ATEC scores in the high-40s primarily due to mixed financial performance: improving cash flow and a healthier TTM balance sheet are offset by a TTM revenue pullback and ongoing net losses. Technicals are a major drag given the strong downtrend versus key moving averages and bearish momentum readings. The earnings call adds modest support via continued EBITDA/margin expansion and demand indicators, but guidance reductions and execution headwinds cap the score, while valuation signals are constrained by a negative P/E and no dividend yield data.

Positive Factors
Surgeon Adoption and Procedure GrowthRapid growth in procedure volumes and new surgeon adoption indicates that ATEC is expanding its clinical footprint and gaining platform acceptance. A broader surgeon base can support recurring implant demand, increase facility penetration, and create durable opportunities for cross-selling its technologies.
Negative Factors
Revenue Pullback and Continuing LossesThe latest revenue contraction weakens confidence that prior growth can translate into a consistently expanding earnings base. Continued operating and net losses also indicate that ATEC has not yet proven durable profitability, leaving execution and scale benefits dependent on renewed demand.

Alphatec Holdings (ATEC) vs. SPDR S&P 500 ETF (SPY)

-80%-60%-40%-20%0%20%ATEC-64.61%SPY+11.73%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$1.08B
Dividend Yield
―
Average Volume (3M)
3.31M
Price to Earnings (P/E)
-12.3
Beta (1Y)
0.62
Revenue Growth
15.34%
EPS Growth
46.31%
Country
US
Employees
913
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Alphatec Holdings Business Overview & Revenue Model

Company Description

Alphatec Holdings, Inc. is a medical technology firm dedicated to engineering and advancing solutions for the surgical management of spinal conditions. Its product array includes the Alpha InformatiX platform, notably the SafeOp Neural InformatiX Sys...

How the Company Makes Money

Alphatec primarily makes money by selling spine-surgery products used in surgical procedures. The core revenue stream is product revenue generated from the sale of spinal implants (e.g., fixation systems, interbody devices and related implants), the...

Alphatec Holdings Earnings Call Summary

Earnings Call Date:Oct 29, 2026(Q3-2026)|% Change Since:-38.96%|Next Earnings Date:Mar 02, 2027
Earnings Call SentimentNeutral

The call presented strong underlying operating momentum, including 13% revenue growth, 20% procedural volume growth, approximately 25% surgeon adoption growth, significant EBITDA and margin expansion, positive free cash flow, and continued progress in Valence and EOS Insight. However, the quarter was described as frustrating because revenue missed expectations, biologics revenue declined, revenue per case fell 5%, thoracolumbar volumes were soft, EOS revenue was flat year-over-year, international supply issues affected adoption, and full-year revenue and free cash flow guidance were reduced. The positive operating and strategic developments were balanced by meaningful execution and market challenges.

Positive Updates

Strong Third-Quarter Revenue and Surgical Growth
Q3 revenue reached $221 million, up 13% year-over-year. Surgical revenue increased 14% to $202 million, while surgical hardware revenue grew 17%.

Negative Updates

Revenue Fell Short of Expectations
Management said Q3 revenue of $221 million was below expectation and described the quarter as frustrating, despite strong demand for ATEC's surgical solutions.

Company Guidance

The company lowered full year 2026 total company revenue expectations to approximately $862 million, representing growth of roughly 13%, including surgical revenue of approximately $789 million, representing growth of approximately 15%, and EOS revenue of approximately $73 million; the outlook includes high-teens surgical case volume growth, a 3% decline in revenue per case, $102 million of year-over-year surgical dollar growth, 17% surgical hardware revenue growth and flat biologics revenue contribution year-over-year, with a temporary international supply constraint expected to impact international sales by about $3 million for the year and resolve as we enter 2027. Adjusted EBITDA is expected to be approximately $137 million, or a 16% margin, representing growth of approximately 47% year-over-year, and free cash flow is expected to be $10 million, implying approximately $15 million in the fourth quarter; the fourth-quarter guide implies an 18% EBITDA ratio, about $12 million associated with surgical volume and $4 million with EOS, with the surgical reduction approximately evenly split between lower biologics expectation and lower procedural volumes, or about $6 million and $6 million.

Alphatec Holdings Financial Statement Overview

Summary

Financials are improving but still mixed. Income statement quality is pressured by a notable TTM revenue pullback and continued net losses despite narrowing losses and slightly positive TTM EBITDA. The balance sheet looks healthier in TTM with very low debt-to-equity (~0.04) and meaningful positive equity, but returns remain negative. Cash flow has turned positive (operating cash flow and small positive free cash flow), though still modest relative to losses and inconsistent versus prior years’ burn.

Income Statement

42Neutral

Balance Sheet

63Positive

Cash Flow

56Neutral
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue839.72M764.15M611.56M482.26M350.87M243.21M
Gross Profit560.07M531.89M424.26M310.20M233.06M157.76M
EBITDA32.32M-39.70M-53.87M-110.59M-102.58M-106.88M
Net Income-86.89M-143.36M-162.12M-186.64M-151.29M-143.03M
Balance Sheet
Total Assets796.75M791.21M775.71M805.21M520.97M572.05M
Cash, Cash Equivalents and Short-Term Investments79.94M160.81M138.84M220.97M84.70M187.25M
Total Debt593.95M619.95M609.94M541.68M395.86M355.43M
Total Liabilities775.44M755.18M766.28M703.49M555.63M492.63M
Stockholders Equity21.30M36.03M9.43M101.72M-34.67M79.42M
Cash Flow
Free Cash Flow4.92M2.78M-137.79M-165.46M-133.41M-141.86M
Operating Cash Flow61.34M45.23M-44.65M-78.48M-75.13M-73.32M
Investing Cash Flow-80.16M-53.41M-93.14M-141.97M-58.28M-157.76M
Financing Cash Flow-56.78M30.02M56.21M356.92M31.23M311.97M

Alphatec Holdings Technical Analysis

Technical Analysis SentimentNegative
Last Price6.94

Price Trends

50DMA9.65Negative
100DMA9.46Negative
200DMA10.04Negative

Market Momentum

MACD-0.91Positive
RSI34.49Neutral
STOCH10.39Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATEC, the sentiment is Negative. The current price of 6.94 is below the 20-day moving average (MA) of 8.64, below the 50-day MA of 9.65, and below the 200-day MA of 10.04, indicating a bearish trend. The MACD of -0.91 indicates Positive momentum. The RSI at 34.49 is Neutral, neither overbought nor oversold. The STOCH value of 10.39 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ATEC.

Alphatec Holdings Risk Analysis

Alphatec Holdings disclosed 78 risk factors in its most recent earnings report. Alphatec Holdings reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.Tariffs and other trade measures could adversely affect our business, results of operations, financial position and cash flowsQ4, 2025
2.Tariffs and other trade measures could adversely affect our business, results of operations, financial position and cash flowsQ3, 2025
3.Tariffs and other trade measures could adversely affect our business, results of operations, financial position and cash flowsQ2, 2025

Alphatec Holdings Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

ATEC against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
MDTMDT81Outperform$130.88B25.1310.60%2.80%9.77%12.28%
SYKSYK75Outperform$120.88B33.6115.61%1.11%7.87%22.82%
GMEDGMED73Outperform$9.27B16.9911.82%―13.35%32.22%
ZBHZBH69Neutral$19.32B25.926.05%0.94%6.98%-2.22%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
ATECATEC49Neutral$1.08B-12.34-547.17%―15.34%46.31%
OFIXOFIX44Neutral$271.87M-5.99-10.32%―2.12%63.59%

* Healthcare Sector Average

Performance Comparison

-60%-40%-20%0%20%ATECMDTOFIXSYKZBHGMEDDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
ATEC and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
ATECAlphatec6.94-12.68-64.63%
MDTMedtronic102.325.205.35%
OFIXOrthofix Medical Inc.6.67-7.79-53.87%
SYKStryker Corp317.54-42.70-11.85%
ZBHZimmer Biomet Holdings102.0913.5915.35%
GMEDGlobus Medical69.99-13.83-16.50%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 31, 2026